A Search Service for Abbreviation / Long Form

â–  Abbreviation / Long Form : HR / hormone receptor

[Related PubMed/MEDLINE]
Total Number of Papers: 850
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HR  (>> Co-occurring Abbreviation)
Long Form:   hormone receptor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database. BCSM, CI, HER2, ILC, OS, PSM, SEER
2020 Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials. AEs, CI, DCR, ORR, OS, PFS
2020 Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. 3yDDFS, BMI, CHT, CI, EBC
2020 Breast Cancer Characteristics and Survival among Users versus Nonusers of Raloxifene. ---
2020 Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. OS, TN
2020 CineBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. ESME, MBC, OS, TFMR
2020 Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. NACT, pCR, RCB
2020 FSIP1 is correlated with estrogen receptor status and poor prognosis. FSIP1
2020 HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. BC, CT, OR, pCR
10  2020 Heterogeneity of genomic profile in patients with HER2-positive breast cancer. ---
11  2020 Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers. ER, HER2, IBC, IHC, PR
12  2020 IL-1-conferred gene expression pattern in ERalpha+ BCa and AR+ PCa cells is intrinsic to ERalpha- BCa and AR- PCa cells and promotes cell survival. IL-1, IPA
13  2020 Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual. AJCC, OS
14  2020 Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities study. BC, ER, FTP, NHWs, PR
15  2020 Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. AI, PFS, TTF
16  2020 Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. HER2, HT, MBC
17  2020 T1-2N1M0 triple-negative breast cancer patients from the SEER database showed potential benefit from post-mastectomy radiotherapy. BCSS, HER2, PMRT, PSM, SEER, TNBC
18  2020 The economic burden of metastatic breast cancer in Spain. MBC
19  2020 The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013. HER2, MBC
20  2020 The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients. ER, MBC, PR
21  2020 The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society. HER2, MC, OS
22  2020 The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis. CI, NCET, NCT, NET, OR, ORR, pCR
23  2019 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes. BC, RS
24  2019 21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes. HER2, OR, RS
25  2019 A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. MBC, mTOR, PFS, PI3K
26  2019 A Population-Based Study on Liver Metastases in Women with Newly Diagnosed Breast Cancer. HER2, SEER
27  2019 A systematic review of the international prevalence of BRCA mutation in breast cancer. gBRCA
28  2019 Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer. CDK, HER2, MBC
29  2019 Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. HER2, OFS, SOFT, STEPP, TEXT
30  2019 Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. ADC, AUC, DCE-MRI, DWI, HER2, pCR
31  2019 Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. CI, HER2
32  2019 Alpelisib: First Global Approval. HER2, PI3K
33  2019 An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). AUC, pCR, RBsig, ROC
34  2019 Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. BC, DFS, FEC-D, KBOG, OS, pCR, TNBC
35  2019 Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. NCT, OR, RS
36  2019 Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. MBC, OS, SystHERs
37  2019 BRCA1 mutation influences progesterone response in human benign mammary organoids. TPA
38  2019 Breast Cancer Mortality in Older and Younger Patients in California. CI, MRR, NCICC
39  2019 Breast cancer survival by immunohistochemistry-determined subtype: A retrospective study. CI, HER2
40  2019 Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer. BBB, CNS, PFS
41  2019 circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. circRNAs
42  2019 Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients. ABC, BC, ctDNA, mPFS, PMS
43  2019 Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases. BCSS, CI, ER, HT, METABRIC, OS, SEER
44  2019 Clinical characteristics and prognostic analysis of ipsilateral supraclavicular lymph node metastases in breast cancer patients: a retrospective study. CI, HER2, ISCLM, TNBC
45  2019 Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer. ctDNA, PBC
46  2019 Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. CI, DFS, DMFS, HER2, MC, RR
47  2019 Clinicopathologic Characteristics and Treatment Outcomes of Patients With Up-Front Metastatic Breast Cancer: Single-Center Experience in India. OS
48  2019 Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. CNB, DFS, FSS
49  2019 Complicated prognostic values of CCL28 in breast cancer by subtype. DFS, RFS
50  2019 Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer. HER2
51  2019 Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. BC, EMA, ET, FDA
52  2019 De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. pCR
53  2019 Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. ---
54  2019 Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. ---
55  2019 Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. HER2, IHC, OS, TNBC
56  2019 Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. DFS
57  2019 Divergent breast cancer incidence trends by hormone receptor status in the state of Sarawak, Malaysia. BC
58  2019 Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? CR, MBC, OS, PD, PFS, PR, SD
59  2019 Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. CI, HRs, OR, OS, pCR, PFS
60  2019 Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature. BC, CDK, ER, HER2, INK4, Rb, WD-DDLPS
61  2019 Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. CI, HER2, NE, OS, PFS
62  2019 Efficacy of PI3K inhibitors in advanced breast cancer. PI3
63  2019 Efficacy of PI3K inhibitors in advanced breast cancer. PI3
64  2019 Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer. BC, ER, HER2, MMR, PR, TMB, TNBC
65  2019 Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens. ER, PR
66  2019 Evaluating triptorelin as a treatment option for breast cancer. AI, LH-RHa, OFS
67  2019 Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. CI, mTOR, PFS
68  2019 Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. BC, BCBM, BM, OS
69  2019 Factors that influence ultrasound evaluation of breast tumor size. HER2
70  2019 Favorable results of patients with pT1a, b, c, lymph node-negative early breast cancer in the long interval. DFS, HER2
71  2019 FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. MBC
72  2019 GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer. AMH, GnRH-a, OVF
73  2019 Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer. ---
74  2019 Hormone Receptor Expression in Multicentric/Multifocal versus Unifocal Breast Cancer: Especially the VDR Determines the Outcome Related to Focality. BC, DFS, ER, OS, PR, TNM, VDR
75  2019 Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor. CI, CNB, HER2, IHC, OR, SS
76  2019 Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. CNS, MBC
77  2019 Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma. ALN, BC, IDC-NST, LRFS, LVI, SLN
78  2019 Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer. HER2, OS, SEER
79  2019 Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015. ---
80  2019 Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer. APC, BCSS, CI, FBC, LN, MBC, OS, PSM, SEER
81  2019 Invasive breast cancer among Alaska Native women in Alaska. AN, HER
82  2019 Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. HER2, IBC, OS
83  2019 Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial. ABC, AIs, CBR, ORR, PFS, TTF
84  2019 MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. HER2, pCR
85  2019 Multigene assays in early breast cancer: Insights from recent phase 3 studies. CT, DFS, ESBC, ET, LN, MGAs, RS
86  2019 Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. ALND, apCR, HER2, NAC, pCR, SLNB, SLNs, TN
87  2019 Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. BMI, ER, HER2, IDC, IHC, NAC, pCR, PR
88  2019 Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial. BC, HER2, pCR, ZOL
89  2019 Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort. BC, cALND, NSM, SLN
90  2019 OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database. AI, IDFS, OFS, OS, SERM
91  2019 Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis. BCS, CSS, RT
92  2019 Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia. BC, HRs, NHB, NHW, ODX RS
93  2019 Outcomes in patients with small node-negative invasive breast cancer. DFS, OS, RR, TNBC
94  2019 Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study. FBC, HaR, HER2, MBC, OS
95  2019 Overview of the relevance of PI3K pathway in HR-positive breast cancer. ER, PI3K
96  2019 Overview of the relevance of PI3K pathway in HR-positive breast cancer. ER, PI3K
97  2019 Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. ABC
98  2019 Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer. CDK, HER2, RB
99  2019 PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. pCR
100  2019 PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer. ---